Search results
Showing 61 to 75 of 88 results for hepatitis c
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).
We have moved Medical technologies guidance 27 to become HealthTech guidance 385. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma in adults.
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.
Telbivudine for the treatment of chronic hepatitis B (TA154)
Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.